Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CTSV | O60911 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256169 | 0.85 | CTSV (0.66) | KDM4EMAPTCTSVCTSLMAOA | |
| SCHEMBL6743988 | 0.83 | CTSV (0.64) | KDM4EMAPTCTSVCTSLMAOA | |
| SCHEMBL690576 | 0.81 | MAOA (0.59) | KDM4EMAPTCTSVCTSLMAOA | |
| SCHEMBL17817109 | 0.81 | KDM4E (0.69) | KDM4EMAPTATMMAOAALDH1A1 | |
| SCHEMBL12646131 | 0.81 | KDM4E (0.50) | KDM4EMAPTATMMAOAALDH1A1 | |
| SCHEMBL16450986 | 0.81 | MAOA (0.55) | KDM4ECTSVCTSLMAOAALDH1A1 | |
| SCHEMBL18487330 | 0.80 | MAOA (0.57) | KDM4ECTSVCTSLMAOAALDH1A1 | |
| SCHEMBL14196709 | 0.80 | MAPT (0.44) | KDM4EMAPTATMCTSVCTSL | |
| SCHEMBL13424610 | 0.78 | KDM4E (0.47) | KDM4EMAPTATMMAOAALDH1A1 | |
| SCHEMBL7255064 | 0.76 | MAOA (0.64) | CTSVCTSLMAOAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457639-B2 | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation | GEORGETOWN UNIVERSITY (US) | 2019-10-29 | — | — | US | disclosed |
| US-10266490-B2 | Radioprotector compounds | GEORGETOWN UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | GEORGETOWN UNIVERSITY (US) | 2015-02-12 | — | — | US | disclosed |
| EP-2484666-A1 | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation | Georgetown University (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2323982-B1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | UNIV GEORGETOWN (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110152339-A1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | GEORGETOWN UNIVERSITY | 2011-06-23 | — | — | US | disclosed |
| EP-2323982-A1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | Georgetown University (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130579-A1 | CANCER THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010019271-A1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2008051523-A2 | CARBAZOLE DERIVATIVES USEFUL AS MEDICAMENTS IN CANCER THERAPY | GEORGETOWN UNIVERSITY (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152339-A1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | RASSF5, RASSF2, MKI67 | KDM4E 1073/4885MAPT 4658/4885ATM 3697/4885 |
| US-10266490-B2 | Radioprotector compounds | DDB1, CASP3, BAD | KDM4E 1496/4885MAPT 4589/4885ATM 420/4885 |
| US-20100130579-A1 | CANCER THERAPY | RASSF5, RASSF2, DNMT1 | KDM4E 331/4885MAPT 3975/4885ATM 2478/4885 |
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | DDB1, CASP3, BAD | KDM4E 1496/4885MAPT 4589/4885ATM 420/4885 |
| US-10457639-B2 | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation | RASSF5, RASSF2, MKI67 | KDM4E 1073/4885MAPT 4658/4885ATM 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.